Core Viewpoint - Via Bio (01873.HK) announced that its wholly-owned subsidiary, Via Incubator, holds a minority stake in Arthrosi Therapeutics, which will be accounted for as a financial asset at fair value in the company's consolidated financial statements. Arthrosi Therapeutics has informed the company that Sobi US Holding Corp. has agreed to acquire it through a merger, and post-completion, the company will no longer hold any equity in Arthrosi Therapeutics. The merger agreement includes an upfront payment of $950 million, subject to customary adjustments, and contingent consideration of up to $550 million [1][2]. Group 1 - Via Incubator holds approximately 3.14% of Arthrosi Therapeutics' equity on a fully diluted and converted basis as of the announcement date [2]. - The buyer, Sobi US Holding Corp., is a wholly-owned subsidiary of Swedish Orphan Biovitrum AB, a global biopharmaceutical company focused on innovative treatments for rare diseases [1][2]. - Arthrosi Therapeutics is a clinical-stage biotechnology company developing pozdeutinurad, a potential next-generation URAT1 inhibitor aimed at lowering serum uric acid levels in patients with progressive gout [2].
维亚生物(01873.HK)：SOBI拟透过并购方式收购Arthrosi Therapeutics